| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1378/CHEST.108.4_SUPPLEMENT.258S |
| P698 | PubMed publication ID | 7555181 |
| P2093 | author name string | J Hirsh | |
| T E Warkentin | |||
| L Poller | |||
| D Deykin | |||
| R Raschke | |||
| J E Dalen | |||
| P433 | issue | 4 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heparin | Q190016 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 258S-275S | |
| P577 | publication date | 1995-10-01 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety | |
| P478 | volume | 108 |
| Q47280059 | A model for collaboration in quality improvement projects: implementing a weight-based heparin dosing nomogram across an integrated health care delivery system |
| Q31939613 | A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators. |
| Q27339266 | A shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function |
| Q71724580 | ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) |
| Q74600262 | Activated clotting time as a screening test prior to catheter-based cardiovascular procedures |
| Q38524632 | Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review |
| Q37368145 | Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C |
| Q33671937 | Anticoagulant therapy in unstable angina. |
| Q43990299 | Anticoagulation therapy in children. |
| Q34751947 | Anticoagulation therapy in patients with venous thromboembolic disease |
| Q37013823 | Antitcoagulant and antiplatelet activities of scolymoside |
| Q33740235 | Antithrombin agents as adjuncts to thrombolytic therapy |
| Q36611360 | Antithrombotic and antiplatelet activities of small-molecule alkaloids from Scolopendra subspinipes mutilans. |
| Q77747914 | Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat |
| Q44632467 | Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor |
| Q87036708 | Approach to acute ischemic stroke in childhood |
| Q78058370 | Argatroban |
| Q73832105 | Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions |
| Q30479354 | Blood flow velocity effects and role of activation delay time on growth and form of platelet thrombi |
| Q40899580 | Brain attack. Acute therapeutic intervention. Antithrombotic and antiplatelet-aggregating drugs. |
| Q37231751 | Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation |
| Q73511216 | Clinical and analytic diagnostic evaluation of deep venous thrombosis of the lower limbs |
| Q73299942 | Clinical and economic effectiveness of an inpatient anticoagulation service |
| Q35566175 | Clinician update: direct thrombin inhibitors in acute coronary syndromes |
| Q44635344 | Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention |
| Q52206720 | Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. |
| Q44777970 | Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis |
| Q35159120 | Current anticoagulant therapy--unmet clinical needs |
| Q40883424 | Current concepts of anticoagulant therapy in pregnancy |
| Q35141098 | Current trends in preoperative patient evaluation and management for podiatric surgeons |
| Q34144439 | Deep vein thrombosis: a clinical review |
| Q51801551 | Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device. |
| Q73587258 | Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) |
| Q34027292 | Direct thrombin inhibitors as adjuncts to thrombolytic therapy |
| Q90749273 | Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update |
| Q33332127 | Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors? |
| Q34571023 | Drugs, their targets and the nature and number of drug targets |
| Q34007527 | Emerging concepts in the diagnosis and management of venous thromboembolism during pregnancy |
| Q38124690 | Evaluation of initial heparin infusion rates for a high-dose protocol |
| Q42057735 | Factor V Leiden and Cardiopulmonary Bypass |
| Q41945608 | Hemocompatibility of silicon-based substrates for biomedical implant applications |
| Q73635489 | Hemostasis Laboratory: Assays for Platelet Function and Von Willebrand Disease |
| Q64059120 | Heparin Differentially Impacts Gene Expression of Stromal Cells from Various Tissues |
| Q33328818 | Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism |
| Q33346855 | Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy |
| Q33502912 | Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy |
| Q38926114 | How We Manage Pediatric Deep Venous Thrombosis |
| Q40344129 | Improvement in long-term ECMO by detailed monitoring of anticoagulation: a case report |
| Q30710756 | In vitro and in vivo characterization of a reversible synthetic heparin analog |
| Q35043999 | Low molecular weight heparin-induced skin necrosis: a case report |
| Q33340903 | Low molecular weight heparins: a guide to their optimum use in pregnancy |
| Q47316212 | Low-Molecular-Weight Heparin in the Initial Treatment of Proximal Deep Vein Thrombosis |
| Q47278479 | Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma |
| Q77919968 | Low-molecular-weight heparins |
| Q41707230 | Low-molecular-weight heparins for acute coronary syndromes |
| Q41635572 | Manipulation of coagulation factors in acute stroke |
| Q33781946 | New-generation anticoagulants: the low molecular weight heparins |
| Q41238308 | Optical sensing of anticoagulation status: Towards point-of-care coagulation testing |
| Q33892529 | Outpatient Therapy of Deep Vein Thrombosis |
| Q41738328 | Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. |
| Q34448244 | Pharmacologic preservation of the hemostatic system during cardiac surgery |
| Q24336588 | Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain |
| Q74244637 | Platelet inhibitors and bleeding in cardiac surgical patients |
| Q74244632 | Platelet inhibitors and cardiac surgery |
| Q92570086 | Polyelectrolyte Complexes between Polycarboxylates and BMP-2 for Enhancing Osteogenic Differentiation: Effect of Chemical Structure of Polycarboxylates |
| Q73236504 | Prevention and management of venous thromboembolism in pregnancy |
| Q33496843 | Prevention and treatment of venous thromboembolism |
| Q77900564 | Problems with monitoring heparin anticoagulation |
| Q34190401 | Regional anesthesia and anticoagulation |
| Q44169606 | Regional anticoagulation with acid citrate dextrose-A for extracorporeal photoimmunochemotherapy. |
| Q77742224 | Risk reduction in the intensive care unit |
| Q58776756 | Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway |
| Q33405311 | Systemic infusion and local irrigation with argatroban effective in preventing clot formation during carotid endarterectomy in a patient with heparin-induced thrombocytopenia |
| Q27349460 | The Extrinsic Coagulation Pathway: a Biomarker for Suicidal Behavior in Major Depressive Disorder |
| Q33685763 | The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. |
| Q37794277 | The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal |
| Q73681259 | Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023) |
| Q73081804 | Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential |
| Q88586250 | Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development |
| Q40853404 | Treatment of deep venous thrombosis and pulmonary embolism. Current recommendations |
| Q36795731 | Treatment of high-risk venous thrombosis patients using low-dose intraclot injections of recombinant tissue plasminogen activator and regional anticoagulation |
| Q34474126 | Treatment options for deep venous thrombosis |
| Q40853392 | Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations |
| Q33333960 | Use of direct thrombin inhibitors in acute coronary syndrome |
| Q28212381 | Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction |
| Q38807947 | Veno-venous extracorporeal membrane oxygenation support during lung volume reduction surgery for a severe respiratory failure patient with emphysema |
| Q77919973 | Venous thromboembolic events in pediatric patients. Diagnosis and management |
| Q47281474 | Weight-based heparin dosing: clinical response and resource utilization |
| Q77478352 | [Epidural lumbar hematoma, epidural anesthesia and low-molecular-weight heparins] |
Search more.